Masimo Corp Rating Reiterated by Zacks (MASI)

Share on StockTwits

Masimo Corp (NASDAQ: MASI)‘s stock had its “neutral” rating reaffirmed by Zacks in a note issued to investors on Monday, Analyst Ratings.Net reports. They currently have a $23.00 target price on the stock. Zacks‘ price objective would indicate a potential upside of 6.43% from the company’s current price.

A number of other firms have also recently commented on MASI. Analysts at TheStreet upgraded shares of Masimo Corp from a “hold” rating to a “buy” rating in a research note to investors on Wednesday, May 15th. Separately, analysts at Citigroup upgraded shares of Masimo Corp from a “sell” rating to a “neutral” rating in a research note to investors on Friday, May 3rd. Finally, analysts at Janney Montgomery Scott initiated coverage on shares of Masimo Corp in a research note to investors on Tuesday, April 9th. They set a “buy” rating on the stock.

One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. Masimo Corp currently has an average rating of “Hold” and an average price target of $23.00.

Shares of Masimo Corp (NASDAQ: MASI) traded up 0.46% during mid-day trading on Monday, hitting $21.71. Masimo Corp has a 52 week low of $18.20 and a 52 week high of $25.35. The stock’s 50-day moving average is currently $19.90. The company has a market cap of $1.229 billion and a P/E ratio of 20.01.

Masimo Corp (NASDAQ: MASI) last released its earnings data on Thursday, May 2nd. The company reported $0.28 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.28. The company had revenue of $135.90 million for the quarter, compared to the consensus estimate of $134.46 million. During the same quarter last year, the company posted $0.27 earnings per share. Masimo Corp’s revenue was up 14.0% compared to the same quarter last year. Analysts expect that Masimo Corp will post $1.14 EPS for the current fiscal year.

Masimo Corporation is a medical technology company that develops, manufactures, and markets non-invasive patient monitoring products that improve patient care.

To view Zacks’ full report, visit www.zacks.com

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Latest News

Walmart Cuts Workers Hours After Making Pay Raises
Walmart Cuts Workers Hours After Making Pay Raises
Pentagon Teaming Up with Boeing and Apple for Wearable Tech
Pentagon Teaming Up with Boeing and Apple for Wearable Tech
One-Hour Delivery by Amazon Arrives in Seattle
One-Hour Delivery by Amazon Arrives in Seattle
Dangerous Bacteria in Ground Beef Shows Study
Dangerous Bacteria in Ground Beef Shows Study
Vital Therapies Stock Plunges Following Failed Trial For Liver Therapy
Vital Therapies Stock Plunges Following Failed Trial For Liver Therapy
Sears Reports Profit for the Quarter But Sales Drop
Sears Reports Profit for the Quarter But Sales Drop


Advertisement
Advertisement
© 2006-2015 Ticker Report. Google+.